Studies on the anti-inflammatory effect of fluoxetine in the rat.
The anti-inflammatory activity of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), was studied on the carrageenan-induced paw inflammation in the rat. Fluoxetine (10-60 mg kg(-1)) given intraperitoneally (i.p.) 30 min before carrageenan, displayed marked anti-inflammatory activity, inhibiting paw oedema by 38.6-77.7% at 2 h post-carrageenan. Fluoxetine administered at time of carrageenan injection or 30 min after carrageenan challenge, markedly inhibited the paw oedema response. Rats administered daily fluoxetine (20 mg kg(-1), i.p.) showed significantly decreased inflammatory response to subplantar carrageenan when examined on the 5th and 14th day of fluoxetine injection. Fluoxetine (10 or 20 mg kg(-1), i.p.) co-administered with indomethacin (IND) (20 mg kg(-1), i.p.), celecoxib (10 mg kg(-1), i.p.) or rofecoxib (4.5 mg kg(-1), i.p.) before carrageenan reduced the anti-oedema effect of indomethacin or celecoxib, but had additive effect to that of rofecoxib. The anti-oedema effects of fluoxetine and melatonin or the tricyclic antidepressant imipramine were additive. In contrast, administration of both fluoxetine and the heterocyclic antidepressant trazodone had no greater anti-inflammatory effect than fluoxetine alone. The anti-oedema effect of fluoxetine was partially suppressed by the opioid antagonist naloxone (4 mg kg(-1), i.p.). Fluoxetine (360 or 720 microg per paw) given into the rat paw with carrageenan reduced the oedema response by 25.4 and 35.3% 4 h post-carrageenan, respectively. It is suggested that fluoxetine alone or co-administered with either imipramine or melatonin would be of benefit in the sitting of neuropathic or inflammatory pain conditions. Both the serotonergic and the opioid systems are likely to be involved in the modulating action of fluoxetine on peripheral inflammation.
Abdel-Salam
Omar M E
OM
Department of Pharmacology, National Research Centre, Tahrir Street, Dokki, Cairo, Egypt. omasalam@hotmail.com
Baiuomy
Ayman R
AR
Arbid
Mahmoud S
MS
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000928:Antidepressive Agents / Q000494:pharmacology; D002351:Carrageenan; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004487:Edema / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D005473:Fluoxetine / Q000008:administration & dosage / Q000494:pharmacology*; D005528:Foot; D007099:Imipramine / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007249:Inflammation / Q000139:chemically induced / Q000517:prevention & control; D007783:Lactones / Q000494:pharmacology; D008550:Melatonin / Q000494:pharmacology; D011720:Pyrazoles; D051381:Rats; D017207:Rats, Sprague-Dawley; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology; D013450:Sulfones; D013997:Time Factors; D014196:Trazodone / Q000494:pharmacology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000928:Antidepressive Agents; D002351:Carrageenan; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors; D005473:Fluoxetine; D007099:Imipramine; D007213:Indomethacin; D007783:Lactones; D008550:Melatonin; D011720:Pyrazoles; D017367:Selective Serotonin Reuptake Inhibitors; D013449:Sulfonamides; D013450:Sulfones; D014196:Trazodone; C116926:rofecoxib